The association of renal tubular dysfunction and methoxyflurane appears to be a distinct entity. Evidence relating methoxyflurane and renal dysfunction is clearly inadequate either to condemn its continued use or to remove it from suspicion. Prospective studies to find out whether there is merely a simple dose–response relationship and to determine the importance of the administration of preanesthctic medication, nitrous oxide, and relaxants with methoxyflurane must be encouraged. Until the results of such studies have been evaluated, the Committee on Anesthesia of the National Research Council urges that this agent should continue to be available in clinical practice.